Jeewon Kim

TL;DR: The recent advances and clinical promise of agonistic anti-CD137 monoclonal antibody therapy are discussed and the potential to improve cancer treatment is discussed.

TL;DR: The discovery of a general class of ALDH inhibitors with a common mechanism of action is reported, and it is demonstrated that these inhibitors undergo an enzyme-mediated β-elimination reaction generating a vinyl ketone intermediate that covalently modifies the active site cysteine residue present in these enzymes.

TL;DR: It is shown here that intratumoural injection of RE doped titania nanoparticles can enhance the efficacy of radiotherapy in vivo, and can result in generation of ROS leading to cell death in a tumour-localized manner.

TL;DR: Data show that pharmacological inhibition ofPKCα effectively reduces mammary cancer metastasis by targeting intravasation and lung seeding steps in the metastatic process and suggest that PKCα-specific inhibitors, such as αV5-3, can be used to study the mechanistic roles of PKC α specifically and may provide a safe and effective treatment for the prevention of lung metastasis of breast cancer patients.

TL;DR: It is found that the proliferation rates of endothelial and tumor cells oscillate asynchronously during the growth of human prostate cancer xenografts and that a PKCbetaII inhibitor may be used to reduce prostate cancer growth by targeting both angiogenesis and tumor cell growth.